These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
618 related articles for article (PubMed ID: 32974366)
21. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
22. Dual alcohol and metabolic-related liver disease: Results from a population of liver transplant patients. Erard D; Villeret F; Chouik Y; Guillaud O; Scoazec JY; Caussy C; Disse E; Boillot O; Hervieu V; Dumortier J Liver Int; 2024 Feb; 44(2):422-432. PubMed ID: 38010979 [TBL] [Abstract][Full Text] [Related]
23. Effect of alcohol consumption on nonalcoholic fatty liver disease. Weng G; Dunn W Transl Gastroenterol Hepatol; 2019; 4():70. PubMed ID: 31620652 [TBL] [Abstract][Full Text] [Related]
24. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714 [TBL] [Abstract][Full Text] [Related]
25. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Serfaty L; Lemoine M Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623 [TBL] [Abstract][Full Text] [Related]
26. Non-Alcoholic Fatty Liver Disease, an Overview. Nd AM Integr Med (Encinitas); 2019 Apr; 18(2):42-49. PubMed ID: 31341444 [TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Pocha C; Xie C Transl Gastroenterol Hepatol; 2019; 4():72. PubMed ID: 31728429 [TBL] [Abstract][Full Text] [Related]
29. Epigenetics in non-alcoholic fatty liver disease. Lee J; Kim Y; Friso S; Choi SW Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327 [TBL] [Abstract][Full Text] [Related]